Search

Displaying results 3031 - 3040 of 10000 in total
  1. Target

    Sodium channel protein type 10 subunit alpha

    go.drugbank.com/bio_entities/BE0000177
    TargetHumans

    Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sod...

    Polypeptides: Sodium channel protein type 10 subunit alpha
  2. Target

    ATP-sensitive inward rectifier potassium channel 10

    go.drugbank.com/bio_entities/BE0009591
    TargetHumans

    May be responsible for potassium buffering action of glial cells in the brain (By similarity). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it (Pu...

    Polypeptides: ATP-sensitive inward rectifier potassium channel 10Synonyms: Potassium channel, inwardly rectifying subfamily J member 10
  3. Target

    Mitogen-activated protein kinase kinase kinase 10

    go.drugbank.com/bio_entities/BE0009462
    TargetHumans

    Activates the JUN N-terminal pathway

    Polypeptides: Mitogen-activated protein kinase kinase kinase 10
  4. Target

    Tumor necrosis factor ligand superfamily member 10

    go.drugbank.com/bio_entities/BE0010497
    TargetHumans

    Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the d...

    Polypeptides: Tumor necrosis factor ligand superfamily member 10
  5. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  6. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.

  7. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

  8. Drug

    MK-8777

    go.drugbank.com/drugs/DB18904
    Investigational

    (174001/P05704/MK-8777-001)). … MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder

    Synonyms: 5H,7H-PYRIDO(3,2-F)PYRROLO(2,1-C)(1,4)OXAZEPIN-5-ONE, 8,9,9A,10-TETRAHYDRO-, (9AS)-
  9. Drug

    Quaternium-15

    go.drugbank.com/drugs/DB14198
    Approved

    In 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326]. … Sensitivity to Quaternium-15 may be identified with a clinical patch test.

  10. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.

    Synonyms: Brilliant blue G, Coomassie Brilliant Blue G